NCT07723261 Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
| NCT ID | NCT07723261 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hellenic Cooperative Oncology Group |
| Condition | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2026-03-30 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Eligibility Criteria
Inclusion Criteria: * Patients with histologically or cytologically proven metastatic PDAC * 1st line treatment with NalIriFOx according to physician's choice * Patients willing to provide a Written Informed Consent Exclusion Criteria: * Patients not matching the above-mentioned inclusion criteria * Neoadjuvant or adjuvant treatment within 6 months from enrolment * Prior treatment with Liposomal irinotecan * Prior treatment of pancreatic cancer in the metastatic setting with chemotherapy or investigational therapy
Contact & Investigator
Athina Christopoulou, MD, PhD
PRINCIPAL INVESTIGATOR
Oncology Unit, General Hospital of Patras "Agios Andreas"
Frequently Asked Questions
Who can join the NCT07723261 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07723261 currently recruiting?
Yes, NCT07723261 is actively recruiting participants. Contact the research team at i_mitrentsi@hecog.ondsl.gr for enrollment information.
Where is the NCT07723261 trial being conducted?
This trial is being conducted at Athens, Greece, Athens, Greece, Athens, Greece, Athens, Greece and 5 additional locations.
Who is sponsoring the NCT07723261 clinical trial?
NCT07723261 is sponsored by Hellenic Cooperative Oncology Group. The principal investigator is Athina Christopoulou, MD, PhD at Oncology Unit, General Hospital of Patras "Agios Andreas". The trial plans to enroll 70 participants.